ProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the-Market Under Nasdaq Rules

Core Viewpoint - ProMIS Neurosciences Inc. has raised $0.8 million through the issuance of pre-funded warrants to an existing healthcare-focused institutional investor, aimed at advancing its clinical development of therapeutic antibodies for neurodegenerative diseases [1][3]. Group 1: Financial Details - The company issued pre-funded warrants to purchase 984,736 common shares at a price of $0.8124 per share, with a nominal exercise price of $0.0001 per share [2]. - The gross proceeds from this offering are expected to be approximately $0.8 million before deducting offering expenses [3]. - The closing of the offering is anticipated to occur around July 24, 2025, subject to customary closing conditions [2][3]. Group 2: Company Overview - ProMIS Neurosciences is a clinical-stage biotechnology company focused on developing therapeutic antibodies targeting toxic misfolded proteins associated with neurodegenerative diseases such as Alzheimer's disease, ALS, and Parkinson's disease [1][6]. - The company utilizes its proprietary target discovery engine, EpiSelect™, to identify Disease Specific Epitopes (DSEs) on misfolded proteins [6].